Answer :
Final answer:
When Tradjenta is used with sulfonylureas or insulin, it is typically necessary to B) decrease the dosage of sulfonylureas or insulin to minimize the risk of hypoglycemia due to the additive effects on insulin secretion.
Explanation:
The question addresses dosing recommendations for sulfonylureas or insulin when used with Tradjenta. Tradjenta (linagliptin) is a medication used to treat type 2 diabetes by increasing incretin levels, which in turn increases insulin secretion to lower blood sugar. When Tradjenta is used in combination with sulfonylureas or insulin, there is a risk of hypoglycemia due to the additive effects on insulin secretion. Therefore, to minimize the risk of hypoglycemia, the dosage of sulfonylureas or insulin might need to be adjusted.
Given this information, the correct response is:
- B) Decrease the dosage of sulfonylureas or insulin
This adjustment is necessary to manage the potential increased risk of hypoglycemia that can occur when these medications are used together, highlighting the importance of individualized patient care and the need to constantly monitor blood glucose levels during treatment.
